Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.66 USD -0.54% Market Closed
Market Cap: 2.8B USD

Intrinsic Value

PTGX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PTGX stock under the Base Case scenario is 15 USD. Compared to the current market price of 45.66 USD, Protagonist Therapeutics Inc is Overvalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PTGX Intrinsic Value
15 USD
Overvaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Protagonist Therapeutics Inc

Valuation History Unavailable

Historical valuation for PTGX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Protagonist Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Protagonist Therapeutics Inc

Current Assets 591.6m
Cash & Short-Term Investments 418.9m
Receivables 168.5m
Other Current Assets 4.2m
Non-Current Assets 153.1m
Long-Term Investments 140.3m
PP&E 12.6m
Other Non-Current Assets 225k
Efficiency

Free Cash Flow Analysis
Protagonist Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Protagonist Therapeutics Inc

Revenue
434.4m USD
Operating Expenses
-181.6m USD
Operating Income
252.8m USD
Other Expenses
22.3m USD
Net Income
275.2m USD
Fundamental Scores

PTGX Profitability Score
Profitability Due Diligence

Protagonist Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional ROIC
Exceptional 1-Year Revenue Growth
40/100
Profitability
Score

Protagonist Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

PTGX Solvency Score
Solvency Due Diligence

Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PTGX Price Targets Summary
Protagonist Therapeutics Inc

Wall Street analysts forecast PTGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTGX is 70.83 USD with a low forecast of 45.45 USD and a high forecast of 86.1 USD.

Lowest
Price Target
45.45 USD
0% Downside
Average
Price Target
70.83 USD
55% Upside
Highest
Price Target
86.1 USD
89% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Protagonist Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PTGX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PTGX Insider Trading
Buy and sell transactions by insiders

PTGX News

Other Videos
What is the Intrinsic Value of one PTGX stock?

The intrinsic value of one PTGX stock under the Base Case scenario is 15 USD.

Is PTGX stock undervalued or overvalued?

Compared to the current market price of 45.66 USD, Protagonist Therapeutics Inc is Overvalued by 67%.

Back to Top